Ultrashort vs Standard-Duration Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing PCI: A Meta-Analysis.
Hendrianus Hendrianus, Diana A Gorog, Udaya S Tantry et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the effects of ultrashort (≤1-month) versus standard-duration dual antiplatelet therapy (DAPT) in 29,232 acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). The study found that ultrashort DAPT did not increase the risk of major adverse cardiac and cerebrovascular events (MACCE) (HR: 1.06; 95% CI: 0.93-1.20; P = 0.38) and significantly reduced major bleeding (HR: 0.47; 95% CI: 0.35-0.64; P < 0.00001).
Key findings
- Ultrashort DAPT did not increase MACCE risk (HR: 1.06; 95% CI: 0.93-1.20; P = 0.38).
- Significantly reduced major bleeding with ultrashort DAPT (HR: 0.47; 95% CI: 0.35-0.64; P < 0.00001).
- Increased MACCE risk observed with intensive abbreviation strategy (HR: 1.37; 95% CI: 1.11-1.69; P = 0.003).
- Bleeding reduction was more pronounced in East Asians (HR: 0.35; 95% CI: 0.25-0.49; P < 0.00001).
Why it matters
The findings suggest that ultrashort DAPT may be a safer option for ACS patients undergoing PCI, as it reduces major bleeding without increasing ischemic events overall. This could influence treatment strategies in diverse patient populations.